XOMAP represents XOMA Royalty Corporation's 8.625% Series A Cumulative Perpetual Preferred Stock, a Nasdaq-listed preferred security of a biotechnology royalty aggregator. XOMA Royalty acquires rights to potential future economics tied to pre-commercial and commercial therapeutic candidates licensed to pharmaceutical and biotechnology companies.
Company news commonly includes quarterly cash dividend declarations for the Series A preferred stock, updates on milestone and royalty receipts, financial results, additions to the royalty and milestone portfolio, royalty-sharing transactions, completed acquisitions and governance changes. Portfolio commentary centers on commercial and investigational therapeutic assets and the royalty streams or milestone payments associated with those assets.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.